
Sangamo Therapeutics, Inc. (0R1D.L)
0R1D.L Stock Price Chart
Explore Sangamo Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0R1D.L price movements and trends.
0R1D.L Company Profile
Discover essential business fundamentals and corporate details for Sangamo Therapeutics, Inc. (0R1D.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
7 Nov 2014
Employees
183.00
Website
https://www.sangamo.comCEO
Alexander D. Macrae Ch.B, M.B., MRCP,
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
0R1D.L Financial Timeline
Browse a chronological timeline of Sangamo Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 16 Mar 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 4 Aug 2025
Revenue estimate is $29.90M.
Earnings released on 12 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.12 by -19.36%, while revenue for the quarter reached $6.44M, missing expectations by -13.21%.
Earnings released on 17 Mar 2025
EPS came in at -$0.11 falling short of the estimated -$0.09 by -21.98%, while revenue for the quarter reached $7.55M, missing expectations by -75.38%.
Earnings released on 13 Nov 2024
EPS came in at $0.04 surpassing the estimated -$0.02 by +362.30%, while revenue for the quarter reached $49.40M, beating expectations by +378.84%.
Earnings released on 7 Aug 2024
EPS came in at -$0.18 falling short of the estimated -$0.15 by -20.73%, while revenue for the quarter reached $356.00K, missing expectations by -94.83%.
Earnings released on 10 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.21 by -27.35%, while revenue for the quarter reached $481.00K, missing expectations by -92.43%.
Earnings released on 13 Mar 2024
EPS came in at -$0.34 falling short of the estimated -$0.26 by -32.43%, while revenue for the quarter reached $2.04M, missing expectations by -74.81%.
Earnings released on 2 Nov 2023
EPS came in at -$0.59 falling short of the estimated -$0.32 by -84.38%, while revenue for the quarter reached $9.40M, beating expectations by +0.41%.
Earnings released on 9 Aug 2023
EPS came in at -$0.66 falling short of the estimated -$0.34 by -95.28%, while revenue for the quarter reached $6.84M, missing expectations by -59.19%.
Earnings released on 27 Apr 2023
EPS came in at $0.12 surpassing the estimated -$0.33 by +138.06%, while revenue for the quarter reached $157.96M, beating expectations by +556.38%.
Earnings released on 23 Feb 2023
EPS came in at -$0.32 surpassing the estimated -$0.36 by +12.35%, while revenue for the quarter reached $27.23M, beating expectations by +1.39%.
Earnings released on 2 Nov 2022
EPS came in at -$0.34 surpassing the estimated -$0.36 by +5.38%, while revenue for the quarter reached $26.46M, missing expectations by -0.48%.
Earnings released on 3 Aug 2022
EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.39%, while revenue for the quarter reached $29.38M, beating expectations by +19.28%.
Earnings released on 2 May 2022
EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.34%, while revenue for the quarter reached $28.23M, beating expectations by +3.46%.
Earnings released on 22 Feb 2022
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.52%, while revenue for the quarter reached $27.99M, beating expectations by +4.34%.
Earnings released on 4 Nov 2021
EPS came in at -$0.33, while revenue for the quarter reached $27.87M.
Earnings released on 30 Sept 2021
EPS came in at -$0.33, while revenue for the quarter reached $28.56M.
Earnings released on 31 Mar 2021
EPS came in at -$0.32, while revenue for the quarter reached $26.28M.
Earnings released on 31 Dec 2020
EPS came in at -$0.29, while revenue for the quarter reached $25.80M.
Earnings released on 30 Sept 2020
EPS came in at -$0.01, while revenue for the quarter reached $57.76M.
0R1D.L Stock Performance
Access detailed 0R1D.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.